Net Income

Rubico Inc.'s new $4 million offering sent its stock tumbling amid severe dilution concerns and red flags over its financial health and ability to fund growth.

At CES 2026, Jinxin Technology unveiled NAMI INSIGHT One, AI-powered learning glasses aiming to revolutionize education. But can it overcome the hurdles?

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

Amid rising regulatory pressure, dxFeed's flawless performance in a critical industry-wide disaster recovery test sets a new benchmark for data reliability.

Manhattan Associates embeds agentic AI and advanced simulation tools into its platform, promising to boost retail productivity, profits, and customer loyalty.

Newly-formed materials giant Magnera reports Q1 results on Feb 5. Investors eye its path to profitability while the industry watches for key market signals.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

Global investment giant Lone Star Funds acquires a second major office asset in South Florida, signaling strong confidence in the region's booming market.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.

The biotech firm lands a major private placement, extending its cash runway to 2028 and signaling strong investor confidence in its novel drug platform.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

Indonesia Energy Corp. starts pre-drilling for two new wells in Sumatra, a key move in its growth strategy and a boost for national energy security.

Former mayoral candidate Luc Rabouin takes the helm at the $500M Foundation of Greater Montréal, bringing his urban development expertise to shape its future.

A new partnership integrates Lilly's powerful TuneLab AI into Schrödinger's LiveDesign, promising to accelerate R&D with a novel privacy-first approach.